NCT05689229

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

Conditions

• Secondary Bacterial Infection in COVID-19 Patients

Interventions

Type	Name	Description
DRUG	Colistin	COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized

Timeline

• Start date: 2021-08-03
• Primary completion: 2021-11-28
• Completion: 2021-12-12
• First posted: 2023-01-19
• Last updated: 2023-01-19

Locations

1 site across 1 country: Egypt